Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade

Nina Eisslera,*, Yumeng Maob,*, David Brodinc, Philippa Reuterswärd c,d, Helene Andersson Sahnd, John Inge Johnsen a, Rolf Kiessling e and Per Kogner d

*These authors contributed equally to this work.

CONTACT Nina Eissler nina.eissler@ki.se; Per Kogner per.kogner@ki.se Childhood Cancer Research Unit, Q6:05, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden

ARTICLE HISTORY
Received 12 July 2016
Revised 29 August 2016
Accepted 29 August 2016

KEYWORDS
Colony stimulating factor 1 receptor (CSF-1R) inhibition; neuroblastoma; PD-1 checkpoint blockade; purinergic enzymes

ABSTRACT
Removal of immuno-suppression has been reported to enhance antitumor immunity primed by checkpoint inhibitors. Although PD-1 blockade failed to control tumor growth in a transgenic murine neuroblastoma model, concurrent inhibition of colony stimulating factor 1 receptor (CSF-1R) by BLZ945 reprogrammed suppressive myeloid cells and significantly enhanced therapeutic effects. Microarray analysis of tumor tissues identified a significant increase of T-cell infiltration guided by myeloid cell-derived chemokines CXCL9, 10, and 11. Blocking the responsible chemokine receptor CXCR3 hampered T-cell infiltration and reduced antitumor efficacy of the combination therapy. Multivariate analysis of 59 immune-cell parameters in tumors and spleens detected the correlation between PD-L1-expressing myeloid cells and tumor burden. In vitro, anti-PD-1 antibody Nivolumab in combination with BLZ945 increased the activation of primary human T and NK cells. Importantly, we revealed a previously uncharacterized pathway, in which T cells secreted M-CSF upon PD-1 blockade, leading to enhanced suppressive capacity of monocytes by upregulation of PD-L1 and purinergic enzymes. In multiple datasets of neuroblastoma patients, gene expression of CD73 correlated strongly with myeloid cell markers CD163 and CSF-1R in neuroblastoma tumors, and associated with worse survival in high-risk patients. Altogether, our data reveal the dual role of activated T cells on myeloid cell functions and provide a rationale for the combination therapy of anti-PD-1 antibody with CSF-1R inhibitor.

Abbreviations: A2A receptor, adenosine A2A receptor; ATP, adenosine triphosphate; CD, cluster of differentiation; cDNA, copyDNA; CFSE, carboxyfluorescein succinimidyl ester; COX-2, cyclooxygenase-2; CSF-1R, colony stimulating factor 1 receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; cSNE, coefficient scores and cross-validation standard errors; CXCL9, 10, and 11, chemokine (C-X-C motif) ligands 9, 10, and 11; CXCR3, C-X-C motif chemokine receptor 3; DC, dendritic cell; DNA, deoxyribonucleic acid; FACS, fluorescence activated cell sorting; IFN, interferon; IL, interleukin; Lym-med, supernatants conditioned by activated lymphocytes; mAB, monoclonal antibody; M-CSF, macrophage colony-stimulation factor; MDSC, myeloid-derived suppressor cells; MRL, mixed lymphocyte reaction; NK cells, natural killer cells; OPLS-DA, orthogonal partial least squares discriminant analysis; PBMC, peripheral blood mononuclear cells; PBS, phosphate buffered saline; PCA, principle component analysis; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; P2X7, P2X purinergic receptor 7; RNA, ribonucleic acid; TAM, tumor-associated macrophage; TNF, tumor necrosis factor; VIP, variable importance scores

Introduction
Immune checkpoint molecules are key rate-limiting pathways in controlling antigen presentation and T-cell activation.1 Blocking antibodies for this pathway, such as anti-CTLA-4 or anti-PD-1 mAb, lead to remarkable outcome in various stages of disease and achieve response rates of up to 30% in metastatic melanoma patients that have failed standard treatments.2,3 However, solid tumors have the capacity to create a hostile environment that suppresses effector immune cell responses and supports growth and metastasis of tumor cells.4 In human cancers, the systemic and local accumulation of suppressive myeloid cells, such as myeloid-derived suppressor cells (MDSCs) or tumor-associated macrophages (TAMs) are documented to pose major challenges for the establishment of long-lasting antitumor immunity after these novel therapies.5-7
Several approaches targeting immuno-suppressive mechanisms are currently under evaluation in combination with checkpoint blockade antibodies. In tumor-bearing mice, concurrent blockade of cyclooxygenase-2 (COX-2), which is a key enzyme in inducing suppressive myeloid cells, significantly enhanced the antitumor effects of checkpoint inhibitors. In addition, targeting immune-suppression mediated by indoleamine-2,3-dioxygenase (IDO) demonstrated promising synergistic effects when combined with checkpoint blockade antibodies. This approach has recently shown efficacy in a phase I clinical trial together with anti-CTLA4 antibody Ipilimumab in patients with metastatic melanoma (NCT02073123).

We and others have previously defined the importance of myeloid cells as immune suppressors and novel therapeutic targets in the childhood neural cancer neuroblastoma. A highly selective inhibitor (BLZ945) targeting CSF-1R signaling potently modulated suppressive myeloid cells in transgenic mice developing spontaneous aggressive neuroblastoma (TH-MYCN model). Further, combining BLZ945 with checkpoint blockade antibodies against the PD-1/PD-L1 axis led to superior tumor control when compared to antibody treatment alone. Antibody treatment alone showed marginal effects on suppressive myeloid cells, which could help explain the ineffectiveness of checkpoint blockade as a single treatment. However, the key components resulting in the superior efficacy of the combination treatment remain elusive.

In this study, we show that combination of CSF-1R inhibitor BLZ945 with antibody blocking of PD-1 signaling leads to significant increase of IFNγ induced chemokines CXCL9, 10, and 11 in myeloid cells. Disrupting signaling of these chemokines hampers T-cell infiltration into tumors and thereby disables tumor control by the combination treatment. In vitro, combination of Nivolumab with BLZ945 increases percentages of CXCR3+ activated human T cells. Upon PD-1 blockade, activated T cells release high levels of M-CSF and increase myeloid cell-mediated immune-suppression, while addition of BLZ945 or of inhibitors targeting adenosine pathways overcomes suppressive mechanisms induced by M-CSF on monocytes. These results highlight a dual role of activated T cells on myeloid cells and provide a rationale for the use of combination immunotherapy.

**Results**

**Combination of BLZ945 and PD-1 blockade leads to effective tumor growth reduction by removing immune-suppression**

We treated transgenic TH-MYCN mice bearing detectable spontaneous neuroblastomas in the abdomen by oral gavage of BLZ945 in combination with i.p. injections of anti-PD-1 antibody for 10 d (Fig. 1A). Control mice remained untreated or were treated with anti-PD-1 antibody alone.

Although anti-PD-1 treatment as a single agent showed marginal therapeutic benefits, combination treatment of BLZ945 with anti-PD-1 antibody led to significant reduction of tumor growth when compared to untreated control mice ($p < 0.004$) or anti-PD-1 single treatment ($p = 0.013$) (Fig. 1A).

In order to dissect the relationships of 59 immune parameters (Table S4) assessed by flow cytometric analysis of spleens and tumor tissues in treatment and control groups, we performed multivariate analysis using the SIMCA platform. The 59 parameters analyzed defining the immune status in spleens and tumors of treated and control mice comprised frequencies of suppressive myeloid cells, i.e., macrophages (CD11b+F4–80+), monocytic (CD11b+Ly6c+Ly6glow) and granulocytic MDSCs (CD11b+Ly6c-Ly6g+), as well as T cell subsets, i.e., CD4+ and CD8+ T cells, and further, expression of activation and maturation markers on these immune subsets, as summarized in Table S4. The results showed high consistency in the principle component analysis (PCA) (Fig. S1A). To compare the immune profiles of different treatment groups, we utilized the OPLS-DA analysis and observed distinct clustering of the groups (Fig. 1B), demonstrating that overall immune cell frequencies and surface marker expressions are distinctly different among the control and treatment groups. Importantly, a direct comparison between the combination treatment (BLZ945+anti-PD-1) and anti-PD-1 single treatment group revealed clear enhancement of T-cell numbers in the combination group, while 19 out of 23 decreased immune parameters in this group were of myeloid lineage (Fig. 1C), confirming that the effects of CSF-1R inhibition were primarily exerted on myeloid cells.

To investigate which immune status contributed to the superior treatment outcome, we analyzed the relationship between immune parameters ($n = 59$, X variables) and tumor weights ($Y$ variables) in the matching animals using the OPLS analysis by calculating coefficient scores and cvSE. Although none of the immune subsets were associated with smaller tumors, we identified several candidates that correlated with larger tumor burdens (Fig. 1D). In detail, the presence of splenic myeloid cells that expressed PD-L1 and CSF-1R at high levels was associated with inefficient antitumor immune responses. Next, we validated the results by comparing the frequencies of the immune cells and demonstrated that combination treatment significantly increased splenic T-cell numbers as well as T-cell infiltration into tumors (Figs. 1E and S1B), and reduced macrophages and MDSCs and their expression of PD-L1 and CSF-1R in spleens and tumors (Figs. 1F and S1C–F).

**Combination treatment increases expression of T-cell recruiting chemokines**

To understand how CSF-1R inhibitor BLZ945 converted insufficient immune response induced by checkpoint blockade antibodies into a highly effective antitumor response, we performed microarray analysis of four individual tumors with comparable weights treated with either BLZ945, anti-PD-1/L1 mAbs, or the combination thereof and compared to untreated tumors (GEO Series accession number GSE79485; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79485). To our surprise, single treatments did not induce consistent changes in gene expression in comparison to control tumors. In contrast, the combination treatment induced significant upregulation of a number of genes (Fig. 2A), most of which were related to interferon pathways (Fig. 2B, highlighted in red). In particular, CXCL9, CXCL10, and CXCL11, which are interferon-induced chemokines, were prominently upregulated (Fig. 2C). In order to investigate the source of the chemokines, we correlated these genes with a number of immune and tumor
markers. Of note, CXCL9, 10, and 11 expression correlated strongly with myeloid marker CD11b ($R = 0.874$, 0.7822, and 0.7718; Fig. 2D), as well as dendritic cell marker CD11c ($R = 0.901$, 0.945, and 0.903; Fig. S2A), but not with T or B cell markers, or the GD2 synthase B4galnt1 tumor marker (Fig. S2B), indicating that myeloid cells are the major producers of these chemokines in the tumors.

To verify these results at the protein level, we conducted intracellular flow cytometry stainings of tumor materials. Our results demonstrated that the production of CXCL9 was significantly elevated in CD11b+ myeloid cells as well as CD45R/B220+ cells, a marker expressed on B cells, activated T cells, and several antigen presenting cells, in tumors of animals that had received the combination therapy (BLZ945+anti-PD-1), whereas single treatments resulted in low to undetectable levels of CXCL9 in these cells (Fig. 2E). These results underline the importance of interferon-regulated myeloid cell repolarization in priming potent antitumor immune responses after the combination treatment.

**Blockade of chemokine signaling abrogates efficacy of combination treatment**

Chemokines CXCL9, 10, and 11 signal via their common receptor CXCR3 and thereby recruit lymphocytes to inflammation sites and enable their penetration into the tumor tissues.\(^{24,25}\) To understand whether chemokine secretion is limited to the tumor tissue or plays a systemic role, we analyzed chemokine levels in sera of treated mice. Similar to tumor tissues, CXCL9 protein levels were substantially increased in sera of mice in the combination group (Fig. 3A), although no CXCL10 could be detected.

To assess the functional role of chemokine signaling via CXCR3, we administered an anti-CXCR3 antibody in addition to the combination treatment (Fig. 3B). Indeed, tumor growth reduction achieved by combination treatment was significantly hampered by CXCR3 blockade ($p < 0.05$, Fig. 3B) and tumor weight distributions clearly visualized the high numbers of large tumors (>1.0 g) and complete absence of small tumors (<0.5 g) (Fig. 3C). Blockade of CXCR3 resulted in very distinct overall immune clustering compared to the combination group (Fig. 3A), although no CXCL10 could be detected.

To assess the functional role of chemokine signaling via CXCR3, we administered an anti-CXCR3 antibody in addition to the combination treatment (Fig. 3B). Indeed, tumor growth reduction achieved by combination treatment was significantly hampered by CXCR3 blockade ($p < 0.05$, Fig. 3B) and tumor weight distributions clearly visualized the high numbers of large tumors (>1.0 g) and complete absence of small tumors (<0.5 g) (Fig. 3C). Blockade of CXCR3 resulted in very distinct overall immune clustering compared to the combination group (Fig. 3A), although no CXCL10 could be detected.

To understand how chemokine secretion is limited to the tumor tissue or plays a systemic role, we analyzed chemokine levels in sera of treated mice. Similar to tumor tissues, CXCL9 protein levels were substantially increased in sera of mice in the combination group (Fig. 3A), although no CXCL10 could be detected.

To assess the functional role of chemokine signaling via CXCR3, we administered an anti-CXCR3 antibody in addition to the combination treatment (Fig. 3B). Indeed, tumor growth reduction achieved by combination treatment was significantly hampered by CXCR3 blockade ($p < 0.05$, Fig. 3B) and tumor weight distributions clearly visualized the high numbers of large tumors (>1.0 g) and complete absence of small tumors (<0.5 g) (Fig. 3C). Blockade of CXCR3 resulted in very distinct overall immune clustering compared to the combination group (Fig. 3A), although no CXCL10 could be detected.

To understand how chemokine secretion is limited to the tumor tissue or plays a systemic role, we analyzed chemokine levels in sera of treated mice. Similar to tumor tissues, CXCL9 protein levels were substantially increased in sera of mice in the combination group (Fig. 3A), although no CXCL10 could be detected.

To assess the functional role of chemokine signaling via CXCR3, we administered an anti-CXCR3 antibody in addition to the combination treatment (Fig. 3B). Indeed, tumor growth reduction achieved by combination treatment was significantly hampered by CXCR3 blockade ($p < 0.05$, Fig. 3B) and tumor weight distributions clearly visualized the high numbers of large tumors (>1.0 g) and complete absence of small tumors (<0.5 g) (Fig. 3C). Blockade of CXCR3 resulted in very distinct overall immune clustering compared to the combination group (Fig. 3A), although no CXCL10 could be detected.

To assess the functional role of chemokine signaling via CXCR3, we administered an anti-CXCR3 antibody in addition to the combination treatment (Fig. 3B). Indeed, tumor growth reduction achieved by combination treatment was significantly hampered by CXCR3 blockade ($p < 0.05$, Fig. 3B) and tumor weight distributions clearly visualized the high numbers of large tumors (>1.0 g) and complete absence of small tumors (<0.5 g) (Fig. 3C). Blockade of CXCR3 resulted in very distinct overall immune clustering compared to the combination group (Fig. 3A), although no CXCL10 could be detected.
Blocking CSF-1R signaling on monocytes augments activation of lymphocytes induced by Nivolumab

In order to evaluate the effects of CSF-1R inhibition and PD-1 blockade on human immune cells, we utilized an *in vitro* model, where freshly isolated primary human immune cells were activated by mixed lymphocyte reactions (MLR) in CFSE-based proliferation assays.

Given the essential role of CXCR3 in T-cell infiltration in response to the combination immunotherapy *in vivo*, we measured the expression of CXCR3 on human T cells. Indeed, proliferating T cells expressed high levels of CXCR3 when activated with microbeads coated with anti-CD3/CD28 agonistic antibodies (Fig. S3A). Thus, we utilized the CFSEdimCXCR3+ T-cell populations as readouts for the subsequent functional analyses.

We hypothesized that monocytes hamper lymphocyte activation after PD-1 blockade. Indeed, depletion of monocytes prior to the functional assays (Fig. S3B) significantly increased the activation of lymphocytes induced by Nivolumab, which is demonstrated by enhanced proliferation of CXCR3+ CD4 and CD8 T cells as well as NK cells (Fig. 4A). Importantly, similar effects were observed when BLZ945 was added to PBMC in addition to Nivolumab, meaning that blockade of CSF-1R on monocytes is able to improve Nivolumab-induced T-cell activation (Fig. 4B). Since CSF-1R is expressed at much higher levels on CD11b+ human myeloid cells (Figs. S3C and D), the additive effects of BLZ945 disappeared when monocytes were depleted (Fig. S3E).

Next, we measured 44 soluble factors in the culture supernatants harvested from three independent proliferation assays using human PBMC and analyzed the association of soluble factors with T-cell activation. As shown in the loading plot of the PCA analysis (Fig. 4C), M-CSF and CXCL10 demonstrated close associations with T-cell activation in our culture system and presented at substantially higher levels when anti-PD-1 antibody was added (Fig. 4D). To confirm that M-CSF was released from activated T cells, we measured intracellular expression of M-CSF when PBMC were activated with increasing doses of anti-CD3/CD28 agonistic antibodies and demonstrated that M-CSF was only upregulated on proliferating Ki67+ T cells (Fig. S4A). When T cells were activated with various numbers of allogeneic monocytes, we also observed higher levels of soluble M-CSF when more CFSEdimCXCR3+ T cells were generated (Fig. S4B).

**T-cell derived M-CSF enhances suppressive functions on healthy human monocytes**

To investigate whether suppressive functions of primary human monocytes were modulated by restraining CSF-1R...
signaling, we tested a number of pharmacological inhibitors and blocking or neutralizing antibodies targeting suppressive mechanisms exploited by myeloid cells in combination with anti-PD-1 antibody in proliferation assays using human PBMC. Notably, attenuating enzymatic functions of CD73, as well as blocking adenosine A2A receptor, but not blocking other inhibitory mechanisms, improved activation of CD8 T cells (Fig. 5A). On the other hand, addition of recombinant human PD-L1 (Fig. 5A) or blocking co-stimulatory pathways reduced activation of T cells (Fig. S5A). To validate our findings, we treated isolated human monocytes with supernatants conditioned by activated lymphocytes (Lym-med) or recombinant human M-CSF. Both treatments induced rapid maturation of primary human monocytes and upregulated their surface expression of CD206 (Fig. S5B). Notably, expression of surface PD-L1 and key enzymes for adenosine production, CD73 and CD39, was increased on monocytes by Lym-med factors or human M-CSF. These effects were sufficiently abrogated by addition of CSF-1R inhibitor (Fig. 5B and C). Meanwhile, expression of HLA-DR, CD80, CD137L, and DC-SIGN or intracellular levels of M-CSF, IFNγ, and IDO were not altered by the treatments on healthy monocytes (unpublished observations). Although CD73 and CD39 were upregulated on subsets of lymphocytes, expression of both proteins was markedly higher on myeloid cells when PBMC were activated (Fig. S5C).

Inhibiting adenosine pathway in addition to the anti-PD-1/BLZ945 combination did not further improve the activation of CD8 T cells, indicating the direct connection between CSF-1R signaling and adenosine production on monocytes (Fig. S5D).

In order to evaluate the clinical importance of myeloid cell-derived adenosine production, we analyzed six publicly available neuroblastoma patient datasets (in total 1687 entries) and demonstrated that expression of CD73 and CD39 genes was only consistently correlated with myeloid cell markers CD163 or CSF-1R (Table 1 and Fig. 5D). A similar trend was also observed in tumor tissues harvested from TH-MYCN mice undergone various treatments (Fig. S6A). M-CSF expression in these tissues also strongly correlated with CD73, CD39, and PD-L1, indicating the involvement of M-CSF in the induction of myeloid cell suppressive mechanisms (Fig. S6B). Of note, expression of high levels of CD73, but not CD39 (unpublished observations) in neuroblastoma tumors, was associated with worse overall survival in high-risk neuroblastoma patients (age > 18 mo) (Fig. 5E), whereas it had no influence on survival of low-risk patients (Fig. S6C).

Despite the relevance of the adenosine pathway in neuroblastoma, treatment of TH-MYCN mice with a combination of anti-PD-1 and anti-CD73 antibodies did not lead to tumor growth inhibition, and a triple combination with CSF-1R inhibitor BLZ945 had to be discontinued due to severe weight loss in mice.
Discussion

Stimulated by the finding that CSF-1R antagonist enabled anti-PD-1 antibody to control tumor growth in the transgenic neuroblastoma mouse model (TH-MYCN), we aimed to dissect the key mechanistic events underlying this combination treatment. Our results revealed that the combination substantially reduced numbers of PD-L1-expressing suppressive myeloid cells in vivo and repolarized intra-tumoral myeloid cells to produce T-cell-recruiting chemokines. Exploiting in vitro models of human primary immune cells, we demonstrated the previously uncharacterized aspect that anti-PD-1 antibody enhanced the release of M-CSF from activated T cells and subsequently promoted suppressive functions on monocytes, mainly through elevating adenosine production and PD-L1 expression. In neuroblastoma patients, the enzymatic machinery of adenosine production was predominantly expressed on myeloid cells and correlated with poor survival in high-risk patients. The main findings are illustrated in Fig. 6.

Despite the clinical success of checkpoint blockade antibodies, a large number of patients failed to establish long-lasting antitumor immunity from the single agent treatment. This could be explained by various mechanisms exerted by solid tumors to grow, metastasize, and prevent antitumor immunity.

The tumor microenvironment holds out several challenges against destruction by immune effector cells such as hypoxic environment and accumulation of suppressive cell types, including regulatory T cells and suppressive cells of the myeloid lineage.

Suppressive myeloid cells have been demonstrated to play a key role in the development of several malignancies and have been correlated to increased stage of malignancies. In neuroblastoma, infiltration of TAMs was correlated to metastatic disease and worse prognosis. Targeting suppressive myeloid cells through CSF-1R inhibition provides a promising approach for solid cancers, particularly when combined with checkpoint inhibitors. Several clinical programs are currently evaluating the safety and therapeutic values of this combinatorial approach (NCT02452424, NCT02526017, NCT02323191, and starting in October 2016 NCT02829723). Therefore, it is of substantial interest to investigate the detailed mechanisms contributing to the superior effects of the combination treatment. Here, we demonstrated that anti-PD-1 antibody as a single treatment failed to control tumor growth, whereas the combination treatment with CSF-1R inhibitor BLZ495 showed superior tumor reduction.

Previous studies demonstrated the ability of single agent BLZ495 to repolarize myeloid cells; others showed that PD-1

Figure 4. BLZ495 augments effects of Nivolumab on primary human lymphocytes. Peripheral blood mononuclear cells (PBMC) from healthy donors were labeled with CFSE and activated in mixed lymphocyte reactions (MLR) with Nivolumab (10 µg/ml) for 6 d and (A) frequencies of CFSEdimCXCR3+ T cells or CFSEdim NK cells were compared when monocytes were present or absent. Alternatively, (B) PBMC were activated in the presence of a fully human IgG4 isotype control (10 µg/ml), DMSO, Nivolumab or combination of Nivolumab and BLZ495 (300 nM) and activation of lymphocytes were compared in nine independent donors in relation to the control group (IgG4 + DMSO). (C) Supernatants from three independent proliferation assays described in (B) were harvested and in total concentrations of 44 soluble factors were measured and visualized in relation to the T-cell activations in the loading plot of a PCA analysis. (D) Concentrations of M-CSF (n = 4) or CXCL10 (n = 3) were measured and demonstrated when PBMC were activated with IgG4 or Nivolumab. *p < 0.05; **p < 0.01; non-parametric Mann–Whitney U test. Each dot in the scatter-dot plots represented an individual blood donor. PCA: principle component analysis.
blockade was able to induce IFNγ-related chemokine production.\textsuperscript{34} We found that only the combination of the two therapies was effective in achieving efficient immune-cell activation resulting in strong antitumor efficacy in the transgenic neuroblastoma mouse model.\textsuperscript{20} Similar to the observations made by Pyonteck et al.,\textsuperscript{31} BLZ945 single treatment did not abolish myeloid cells in the tumor, probably due to the presence of cytokines sustaining myeloid cell survival in the tumor microenvironment.\textsuperscript{20} Our further analysis revealed that in addition to the removal of suppressive myeloid cells, repolarization of myeloid cells by enhancing CXCL9, 10, and 11 production presented an essential regulator. Indeed, blocking their common receptor CXCR3\textit{in vivo} prevented the therapeutic effects, possibly due to counteracting trafficking of effector T cells across tumor vessels.\textsuperscript{25} These findings coincide with the recent notion that IFN-regulated chemokines CXCL9, 10, and 11 are of favorable clinical outcomes in patients with cancers.\textsuperscript{35-38} Hence, it is reasonable to hypothesize that chemokines derived from activated myeloid cells may contribute to a beneficial immune texture in the tumor microenvironment.

One of the key challenges of the current checkpoint blockade therapy is the early identification of patients who are likely to respond to the treatment. We were among the first to report that frequencies and phenotypes of myeloid cells were rapidly altered in response to anti-CTLA-4 blocking antibody Ipilimumab in melanoma patients and could be correlated to poor treatment outcome.\textsuperscript{39-41} However, potential predictive biomarkers remain to be discovered in patients receiving anti-PD-1 therapy. Previous reports proposed that expression levels of PD-L1 on tumor cells were associated with clinical outcomes of the treatment.\textsuperscript{41} In the murine model of this study, we monitored simultaneously 59 immune cell parameters and demonstrated that splenic myeloid cells expressing PD-L1 and CSF-1R at high levels were associated with larger tumor burdens. Given that PD-L1 is also expressed by various immune cells in the tumor tissues,\textsuperscript{42} these markers may also have predictive value in human cancers.

It is well described that suppressive myeloid cells inhibit effector T-cell functions.\textsuperscript{5} However, less is known about how activated T cells could influence the functions of suppressive myeloid cells. Pinton et al. recently described that IL-10 released by activated T cells sustained activities of murine MDSCs.\textsuperscript{43} We screened 44 soluble factors released by primary human immune cells after PD-1 blockade and identified a strong association...
between M-CSF production and T-cell activation. Similar to the in vivo efficacy, blocking CSF-1R signaling on primary human monocytes enhanced the effects of anti-PD-1 antibody. M-CSF is a crucial factor involved in myeloid cell homeostasis and described to be released by activated T cells during autoimmune conditions.\textsuperscript{44,45} Thus, PD-1 blockade is likely to trigger intrinsic negative feedback mechanisms, i.e., release of M-CSF as shown here, which attenuate the antitumor efficacy.

Fast-proliferating cells are featured by over-production of ATP, which could directly enhance suppressive functions of myeloid cells through P2X7 receptor.\textsuperscript{46} Alternatively, the enzymatic machinery led by CD39 and CD73 enables conversion of ATP to extracellular adenosine and suppresses T cells through adenosine A2A receptors.\textsuperscript{47} Therapeutic inhibition of CD73 or adenosine A2A receptor\textsuperscript{49,50} improved antitumor efficacy. Of note, expression of the CD73 gene was strongly correlated with CSF-1R gene expression and predicted poor clinical outcome in patients with high-risk neuroblastoma. These findings provide deeper understanding of how blockade of CSF-1R in cancer patients might counterbalance various suppressive mechanisms exerted by myeloid cells. The strong correlation of M-CSF in tumors of TH-MYCN mice to T cell markers, as well as to suppressive markers, underlines the relevance of these findings in the in vivo situation.

In conclusion, we believe that T-cell activation in response to PD-1 blockade may play a dual role in regulating myeloid cells. On the one hand, myeloid cell repolarization that is driven by IFN\textgamma; guides T-cell infiltration by chemokines, whereas on the other hand, M-CSF or other inflammatory mediators released from T cells induce intrinsic resistant mechanisms through enhancing suppressive functions on myeloid cells. The described effects of anti-PD-1 antibody on T-cell activation, in particular M-CSF release, and consequently on myeloid cell suppressive functions provide a rationale for the combination therapy with CSF-1R inhibitor. Hence, we suggest that combinational strategies targeting multiple regulatory mechanisms in the tumor microenvironment are of particular advantage in designing novel antitumor immunotherapies.

### Materials and methods

#### Animals

TH-MYCN mice\textsuperscript{21} were obtained from the Mouse Model of Human Cancer Consortium Repository (N16 backcross to the 129 x 1/SvJ background) and kept as continuous inbreeding. All animal studies were approved by the local authorities and conducted under the ethical permit number N42/14. For therapy studies, heterozygous mice were palpated every second day and treatment started on the day tumors were first palpable (day 0). For in vivo treatment, anti-PD-1 blocking antibody (clone RMPI-1.14, Bioxcell) was injected intraperitoneally (i.p.) on days 0, 3, and 6. Alternatively, a highly selective CSF-1R tyrosine kinase inhibitor BLZ945 (Novartis) was dissolved in 20% DMSO.

| Cell types     | Patient datasets | Correlation coefficient ($R$) |  |
|----------------|------------------|-------------------------------|--|
| Myeloid cells  | Kokak ($n = 649$) | SEQC ($n = 498$) | Asgharzadeh ($n = 249$) | Seeger ($n = 102$) | Maris ($n = 101$) | Versteeg ($n = 88$) |
| CD73 vs CD163  | 0.326            | 0.467                         | 0.062                       | 0.332                       | 0.522                       | 0.466          |
| CD39 vs CD163  | 0.588            | 0.484                         | 0.734                       | 0.558                       | 0.362                       | 0.609          |
| CD39 vs CSF1R  | 0.314            | 0.540                         | NA                          | 0.402                       | 0.226                       | 0.487          |
| CD39 vs CSF1R  | 0.530            | 0.496                         | NA                          | 0.628                       | 0.071                       | 0.597          |
| Tregs          | CD73 vs FOXP3    | -0.245                       | 0.200                       | 0.084                       | 0.038                       | NA             |
|                | CD39 vs FOXP3    | -0.239                       | 0.108                       | 0.035                       | 0.019                       | NA             |
| B cells        | CD73 vs CD19     | 0.107                        | 0.239                       | 0.301                       | 0.207                       | 0.060          |
|                | CD39 vs CD19     | 0.008                        | 0.189                       | 0.298                       | 0.353                       | 0.008          |
| Tumors\textsuperscript{2} | CD73 vs B4GALNT1 | -0.050                       | -0.053                      | -0.069                      | -0.126                      | -0.112         |
|                | CD39 vs B4GALNT1 | -0.090                       | -0.114                      | -0.145                      | -0.040                      | -0.141         |

\textsuperscript{2}B4GALNT1 ($eta$-1,4-N-acetyl-galactosaminyl transferase 1) is responsible for GD2 synthesis, which is a disialoganglioside commonly over-expressed in human neuroblastoma. $R > 0.4$; Black: $0.2 < R < 0.4$; NA: gene not available.

---

**Table 1.** Correlation analysis of CD39/CD73 in human neuroblastoma tumor samples.

**Figure 6.** Regulation of myeloid cells by activated T cells in response to anti-PD-1 therapy. The graph summarizes the major findings of this study. Anti-PD-1 antibody treatment results in the release of IFN\textgamma; by activated T cells and re-activates myeloid cells to produce chemokines CXCL9, 10, and 11, which recruit T cells via CXCR3 signaling. At the same time, activated T cells secret M-CSF and enhance suppressive potentials of myeloid cells, such as upregulation of PD-L1 as well as CD39/CD73 expression. The adenosine catabolizing enzymes CD39/CD73 convert ATP to adenosine, which can inhibit T cells via A2A receptors.
Capture\textsuperscript{\textregistered} at 16 mg/mL and delivered daily by oral gavage at the dose of 200 mg/kg\textsuperscript{20,31} in combination with the PD-1 blocking antibody. In some experiments, a CXCR3 blocking antibody (clone CXCR3-173, Bioxcell) was injected i.p. in addition to the antibody. In some experiments, a CXCR3 blocking antibody at a dose of 200 mg/kg\textsuperscript{20,31} in combination with the PD-1 blocking antibody. In some experiments, a CXCR3 blocking antibody (clone CXCR3-173, Bioxcell) was injected i.p. in addition to the antibody. In some experiments, a CXCR3 blocking antibody at a dose of 200 mg/kg\textsuperscript{20,31} in combination with the PD-1 blocking antibody.

**Microarray analysis**

RNA isolation and purification, as well as microarray analysis of snap frozen murine tumor tissue, were performed by the Bioinformatics and Expression analysis core facility (BEA) at Karolinska Institutet. RNA was isolated using QIAGEN RNaseasy Mini Kit. Samples were homogenized using a QIAGEN TissueLyzer and further processed in a QIAGEN QIAcube. 75 ng of total RNA was reverse transcribed and labeled using the Affymetrix Whole Transcript (WT Plus) Assay. The resulting cDNA was hybridized to a GeneTitan plate (Mouse Gene 2.1 ST). Raw expression data were analyzed using Affymetrix Expression Console v1.4.1 using the RMA procedure. Sample groups were compared using unpaired t-tests.

**Isolation of human primary immune cells**

Primary human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats of healthy blood donors by Ficoll gradient centrifugation (GE Healthcare). In order to deplete monocytes, 10 μL RosetteSep human monocyte depletion cocktail (StemCell Technologies) was added to 10 mL buffy coat and incubated at room temperature for 20 min, prior to centrifugation. In order to purify primary human monocytes, PBMC were incubated with microbeads coated with anti-CD14 mAb followed by isolation using LS columns (Miltenyi Biotech).

**Functional analysis of human immune cells**

Unless otherwise stated, all in vitro experiments were performed using IMDM medium (Invitrogen) supplemented with 10% pooled human AB serum (Karolinska University Hospital). To evaluate the effects of treatments, PBMC or monocyte-depleted PBMC (mono-dep cells) were incubated with 1.4 μM CellTrace\textsuperscript{TM} CFSE (Life Technologies) for 6 min at room temperature. Cells were washed two times with PBS (Life Technologies) and 3 x 10^5 cells were seeded at 4:1 ratio with previously frozen and freshly thawed allogeneic monocytes in a 96-well flat bottom plate (Corning). Next, BLZ945 (300 nM, Novartis) or Nivolumab (10 μg/mL, Bristol-Myers Squibb) was added alone or in combination to the wells. Matching concentrations of DMSO (Life Technologies) or a human IgG4 isotype control (Biolegend) were added as controls. In some experiments, different pharmacological inhibitors or blocking/neutralizing antibodies (Tables S1 and S2) or 10 μg/mL of human recombinant PD-L1 (AcroBiosystems) were tested in combination with Nivolumab. After 6 d, cells were harvested and proceeded to flow cytometric analysis.

In order to measure the intracellular production of M-CSF, freshly isolated PBMC were activated for 3 d with microbeads coated with anti-CD3/CD28 mAb (0.5–3 μL, Life Technologies) in a 96-well U bottom plate (Corning). During the final 12 h, GolgiPlug\textsuperscript{TM} protein transport inhibitor (BD Biosciences) was added at 1:1500 dilution to the wells and cells were harvested for FACS analysis.

**Cytokine and chemokine analysis**

In total, 43 human soluble factors were measured in the culture media harvested from three independent proliferation assays using a 37-parameter Bio-Plex\textsuperscript{TM} Human Inflammation Panel including IL-27(p28), gp130/sIL-6Rβ, IL-34, IL-22, sIL-6Rα, IFN-γ2, IFN-γ, IL-26, MMP-2, IL-12(p40), IL-19, IL-20, IL-29 (IFN-α1), IL-35, IL-32, BAFF/TNFSF13B, IL-2, IL-11, APRIL/ TNFSF13B, MPP-1, IFN-β, MMP-3, sCD163, Pentraxin-3, LIGHT/TNFSF14, TSLP, sCD30/TNFSF8, IL-8, IL-10, TWEAK/TNFSF12, Osteocalcin, IL-28A/(IFN-α2), sTNF-R2, chitinase-3-like1, sTNF-R1, IL12(p70), and Osteopontin (Bio-Rad) and a 13-parameter LEGENDplex\textsuperscript{TM} Human Anti-Virus Response Panel consisting of IL-1β, IL-6, TNF-α, IP-10 (CXCL10), IFN-β1(IL-29), IL-8, IL12(p70), IFN-α2, IFN-β2/3 (IL28-A/B), GM-CSF, IFN-β, IL-10, and IFNγ (Biolegend), according to manufacturers’ protocol. The overlapping factors between the two kits were added. Levels of human soluble M-CSF were determined by ELISA (R&D systems). Concentrations of CXCL9 and CXCL10 in sera of treated or control mice were analyzed by a Legendplex assay (Biolegend).

**Treatment of human primary monocytes**

To generate lymphocyte-conditioned media (Lym-med), 6.5 x 10^6 monocyte-depleted human PBMC were co-cultured with allogeneic monocytes at 6:1 ratios in 3 mL culture medium per well in a six-well plate. The conditioned media were harvested and pooled after 6 d and stored in aliquots at −80°C. To evaluate the effects of Lym-med or M-CSF on primary human monocytes, 1 x 10^6 freshly isolated monocytes were seeded in 600 μL culture medium in a 24-well plate (Corning) with various concentrations of Lym-med (5–20%) or recombinant human M-CSF (3.125–200 ng/mL, carrier-free, Biolegend), in the presence of DMSO or 1 μM BLZ945. Cells were harvested by carefully scraping the wells after 2 d (M-CSF) or 4 d (Lym-med) and phenotypic changes or intracellular protein levels of the monocytes were determined by flow cytometry.

**Flow cytometric analysis**

Information regarding antibodies used for flow cytometry was summarized in Table S3. FACS stainings were performed in 96-well V bottom plates. Up to 1 x 10^6 cells were placed in 96-well plates, washed two times with PBS, and stained for 20 min at room temperature with pre-mixed surface marker antibodies.
and life dead markers, near infra-red, Live/Dead fixable blue, or aqua dead cell marker (Invitrogen) in 20–50 μL PBS. After washing in PBS, cells were resuspended in FACS buffer (PBS+10% heat-inactivated FCS) and stored at 4°C before measurements. For intracellular stainings (i.e.), cells were fixed in BD Cytofix/Cytoperm buffer (BD Bioscience) for 30 min at room temperature and washed with 1× BD PermWash (BD Bioscience) buffer and incubated with intracellular antibodies in 1× BD PermWash buffer for 45 min at room temperature. After a final wash, cells were acquired at the BD LSRII cytometer (BD Bioscience) or the NovoCyte Flow Cytometer (ACEA Biosciences) and analyzed by FlowJo software (Tristar, Inc.) or NovoExpress software (ACEA), respectively.

**Multivariate analysis**

All multivariate analyses were performed using the SIMCA software (version 14, Umetrics). In brief, raw data were modeled using PCA and the outliers were controlled based on the 95% confidence interval (CI) margins. The correlations between 44 human inflammatory soluble factors and frequencies of activated (CFSE diminCXCR3+) CD4+ and CD8+ T cells were demonstrated using loading plots of the PCA analysis. For the animal studies, frequencies of 59 splenic and intra-tumoral immune parameters were recorded first with FACS in control mice \( (n = 9) \), anti-PD-1-treated mice \( (n = 6) \), and mice that received combination treatments \( (n = 6) \), and differences between the chosen two groups were compared and summarized in the PCA analysis. Furthermore, immune profiles of control and different treatment groups were modeled and compared using the orthogonal partial least squares discriminant analysis (OPLS-DA). To investigate the importance of the immune subsets (X variables) to tumor weights (Y variables), we performed the OPLS analysis and selected the key contributors based on the variable importance scores (VIP), coefficient scores and cross-validation standard errors (cvSE).

**Patient datasets**

In order to investigate the expression and prognostic values of the adenosine pathway, we analyzed publicly available expression datasets (‘R2: microarray analysis and visualization platform’, [http://r2.amc.nl](http://r2.amc.nl)). In total, six independent patient cohorts were selected for correlation analyses (Spearman coefficients and two-tailed t-tests) and the largest patient cohort (Kocak, \( n = 649 \)) was utilized to explore the prognostic values of CD73 gene expression in neuroblastoma patients.

**Statistical analysis**

Data were collected from several independent experiments and edited in GraphPad Prism, unless indicated differently. We first tested Normal distribution and equal variant of the datasets, followed by Student’s t-tests or non-parametric, Mann–Whitney \( U \) tests (as stated in the figure legends). All results were presented as means±SD and representative histograms or pictures were selected based on the average values.

**Study approval**

Mice were maintained in the Department of Comparative Medicine, Karolinska Institutet. All animal studies were approved by the local authorities and conducted under the ethical permit number N42/14.

**Data and materials availability**

The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus \(^5\) (Edgar et al., 2002) and are accessible through GEO Series accession number GSE79485 ([https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79485](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79485)).

CSF-1R inhibitor BLZ945 was provided through an MTA from Novartis.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

The authors appreciate the excellent technical support from Ms. Lotta Elfman. We are grateful for the help from Ms. Sandra Olsson and Michelle Gustafsson from the AKM animal facility at the Karolinska Institutet during our animal experiments. We also would like to thank the core facility at Novum, BEA, Bioinformatics and Expression Analysis, which is supported by the board of research at the Karolinska Institutet and the research committee at the Karolinska University Hospital. We further thank Novartis for providing the BLZ945 compound and the assistance received from Drs. James Sutton and Marion Wiesmann during the process.

**Funding**

The study was generously supported by the Swedish Childhood Cancer Foundation, the Neuroblastoma and CNS Tumor Network of Sweden (NBCNS), the Swedish Cancer Society, the Swedish Research Council, the Swedish Foundation for Strategic Research (SSF), the Novel Neuroblastoma Biomarkers of Clinical Relevance Consortium (NNBCR), the Cancer Society of Stockholm, the ALF-project grant from Stockholm City Council, the Knut and Alice Wallenberg’s Foundation, the Mäta and Gunnar V. Philipson Foundation, the Cancer Research Foundation of Radiumhemmet, and the Karolinska-sponsored Center for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC). In addition, N.E. is supported by a post-doctoral fellowship from the Swedish Childhood Cancer Foundation, the Neuroblastoma and CNS Tumor Network of Sweden (NNBCR), the Cancer Society of Stockholm, the ALF-project grant from Stockholm City Council, the Knut and Alice Wallenberg’s Foundation, the Mäta and Gunnar V. Philipson Foundation, the Cancer Research Foundation of Radiumhemmet, and the Karolinska-sponsored Center for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC). In addition, N.E. is supported by a post-doctoral fellowship from the Swedish Childhood Cancer Foundation and Y.M. received an individual grant from the Robert Lundberg Memorial Foundation.

**ORCID**

Philippa Reuterswärd [http://orcid.org/0000-0003-0344-8049](http://orcid.org/0000-0003-0344-8049)
Rolf Kiessling [http://orcid.org/0000-0003-0663-5763](http://orcid.org/0000-0003-0663-5763)
Per Kogner [http://orcid.org/0000-0002-2202-9694](http://orcid.org/0000-0002-2202-9694)

**References**

1. Pardoll DM. The blockade of immune checkpoints in cancer immu
notherapy. Nat Rev Canc 2012; 12:252-64; PMID:22437870; http://dx.
doi.org/10.1038/nrc3239
2. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N
Engl J Med 2010; 363:711-23; PMID:20252992; http://dx.doi.org/10.1056/NEJMoa1003466

3. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmier R, Neys B, Hoeller C, Khushalani NI, Miller WH Jr., Lao CD et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-84; PMID:25795410; http://dx.doi.org/10.1016/S1470-2045(15)00767-8

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:64-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013

5. Mantovani A, Allavena P. The interaction of antitumor therapies with tumor-associated macrophages. J Exp Med 2015; 212:435-45; PMID:25753580; http://dx.doi.org/10.1084/jem.20150295

7. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumors. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175

8. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy targeting CTLA-4. J Exp Med 2013; 210:1389-402; PMID:23506545; http://dx.doi.org/10.1084/jem.20130175

10. Pranger S, Koblish K, Horton B, Scherle PA, Neumann R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4 and PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J Immunother Cancer 2014; 2:3; PMID:23829760; http://dx.doi.org/10.1158/1078-0432.CCR-14-0635

12. Zelmay S, van der Veen AG, Botcher JP, Nselgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R. Cyclooxygenase-dependent inhibition of tumor-derived prostaglandin-e2 blocks the induction of tumor growth through evasion of immunity. Cell 2015; 162:1257-70; PMID:26343581; http://dx.doi.org/10.1016/j.cell.2015.08.015

13. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L et al. Durable therapeutic efficacy of anti-CTLA-4, anti-PD-1, and anti-IDO blockade in spontaneous neuroblastoma. Cancer Immunol Immunother 2014; 2:3; PMID:23633486; http://dx.doi.org/10.1186/0008-5472.CAN-2014-12-4115

19. Carlson LM, Kogner P. Neuroblastoma-related inflammation: may small doses of aspirin be suitable for small cancer patients? Oncoimmunology 2013; 2:24658; PMID:24073359; http://dx.doi.org/10.4161/onci.24658

22. Mao Y, Isslers N, Le Blanc K, Johnsen JL, Kogner P, Kisieling R. Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin Cancer Res 2016; 22:3849-59; PMID:26957560; http://dx.doi.org/10.1158/1078-0432.CCR-15-1912

26. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16:2985-95; PMID:9214616; http://dx.doi.org/10.1093/emboj/16.11.2985

27. Rasmuson A, Segerstrom L, Nethander M, Finnman J, Elfman LH, Javnannardi N, Nilsson S, Johnsen JJ, Martinsson T, Kogner P. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS One 2012; 7:e51297; PMID:23284678; http://dx.doi.org/10.1371/journal.pone.0051297

28. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-JB, Ku AW, Frelinger JG, Ondusi K, Gajewski TF et al. Non-redundant requirement for CXCR3 signalling during tumorigenic T-cell trafficking across tumor vascular checkpoints. Nat Commun 2015; 6:7458; PMID:26109379; http://dx.doi.org/10.1038/ncomms8458

30. Khaled YS, Ammori BJ, Elkord E. Increased levels of granulocytic myeloid-suppressor cells in peripheral blood and tumor tissue of pancreatic cancer patients. J Immunol 2014; 2014:897897; PMID:24741628; http://dx.doi.org/10.1155/2014/897897

31. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19708109; http://dx.doi.org/10.1038/nri24658

32. Diaz-Montero CA, Salem ML, Nishimura MI, Garrett-Mayor E, Cole DJ, Montero AJ. Increased circulating myeloid-suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59; PMID:18446337; http://dx.doi.org/10.1007/s00262-008-0523-4

35. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-JB, Ku AW, Frelinger JG, Ondusi K, Gajewski TF et al. Non-redundant requirement for CXCR3 signalling during tumorigenic T-cell trafficking across tumor vascular checkpoints. Nat Commun 2015; 6:7458; PMID:26109379; http://dx.doi.org/10.1038/ncomms8458

36. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V et al. CSF-1R inhibitors alter macrophage polarization and blocks glioma progresion. Nat Med 2013; 19:1264-72; PMID:24056773; http://dx.doi.org/10.1038/nm.3337
malignant lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012; 2:765; PMID:23097687; http://dx.doi.org/10.1038/srep00765

36. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008

37. Stoll G, Enot D, Mlecnik B, Galon J, Kroemer G. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology 2014; 3:e27784; PMID:24790795; http://dx.doi.org/10.4161/onci.27784

38. Ascierto ML, Kmiecik M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2012; 131:871-80; PMID:21479927; http://dx.doi.org/10.1007/s10549-011-1470-x

39. Pico de Coana Y, Poschke I, Gentilcore G, Mao Y, Nystrom M, Hansson J, Masucci GV, Kiessling R. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Res 2016; 76:1168-84; PMID:26700461

40. Gebhardt C, Sevko A, Jiang H, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012; 2:765; PMID:23097687; http://dx.doi.org/10.1038/srep00765

41. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012; 2:765; PMID:23097687; http://dx.doi.org/10.1038/srep00765

42. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Rosol AD, McDermott DF, Powederly JD, Gettinger SN et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011

43. Pinton L, Solito S, Damuzzo V, Francescato S, Pozzuoli A, Berizzi A, Mocellin S, Rossi CR, Bronte V, Mandruzzato S. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget 2016; 7:1168-84; PMID:26700461

44. Fretier S, Besse A, Delval A, Garcia M, Morel F, Leprivey-Lorget V, Wijdenes J, Praloran V, Lecron JC. Cyclosporin A inhibition of macrophage colony-stimulating factor (M-CSF) production by activated human T lymphocytes. J Leukoc Biol 2002; 71:289-94; PMID:11818450

45. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8:533-44; PMID:18551128; http://dx.doi.org/10.1038/nri2356

46. Bianchi G, Vuerich M, Pellegrini P, Marinielli D, Emonti L, Marigo I, Bronte V, Di Virgilio F, Pistoia V, Raffaghello L. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis 2014; 5:e1135; PMID:24651438; http://dx.doi.org/10.1038/cddis.2014.109

47. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013; 13:842-57; PMID:24226193; http://dx.doi.org/10.1038/nrc3613

48. Allard B, Pommy S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 2013; 19:5626-35; PMID:23983257; http://dx.doi.org/10.1158/1078-0432.CCR-13-0545

49. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8:533-44; PMID:18551128; http://dx.doi.org/10.1038/cddis.2014.109

50. Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res 2014; 74:3652-8; PMID:24986517; http://dx.doi.org/10.1158/1158-8568.CIR-13-0016

51. Kocak H, Ackermann S, Hero B, Kahlert Y, Oberthuer A, Juraeva D, Klopas CM, Schell MJ, Sondak VK, Weber JS, Muller JO. Baseline peripheral blood biomarkers associated with clinical response to ipilimumab. J Natl Cancer Inst 2016; 108:971-8; PMID:27539764; http://dx.doi.org/10.1158/1078-0432.CCR-15-0676

52. Asgharzadeh S, Pique-Fregin R, Sposto R, Wang H, Yang Y, Shi-mada H, Matthay K, Buckley J, Ortega A, Seeger RC. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006; 98:1193-203; PMID:16954472; http://dx.doi.org/10.1093/jnci/dji330

53. Molenaar JJ, Koster J, Zwijsenburg DA, van Sluis P, Valentinij LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J et al. Baseline peripheral blood biomarkers associated with clinical response to ipilimumab. J Natl Cancer Inst 2016; 108:971-8; PMID:27539764; http://dx.doi.org/10.1158/1078-0432.CCR-15-0676

54. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI database for microarray and genome-wide expression data. Nucleic Acids Res 2002; 30:207-10; http://dx.doi.org/10.1016/S0779-6879(06)11091-8